NDA 203505 · Duchesnay
Osphena
Ospemifene · Oral · Estrogen Agonist/Antagonist
NovelLast checked: Nov 20, 2026Latest source record: Feb 7, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Feb 26, 2013
Approved uses
2
Original approval plus efficacy supplements
Registered trials
10
6 Phase 3, 0 recruiting
FAERS reports
2,605
481 serious, 4 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ENDOMETRIAL CANCER and CARDIOVASCULAR DISORDERS WARNING: ENDOMETRIAL CANCER and CARDIOVASCULAR DISORDERS See full prescribing information for complete boxed warning. OSPHENA is an estrogen agonist/antagonist with tissue selective effects. In the endometrium, OSPHENA has estrogen agonistic effects. There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Perform adequate diagnostic measures, including directed and random endometrial sampling when indicated, to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding [see Warnings and Precautions (5.2) ]. Estrogen-alone therapy has an increased risk of stroke and deep vein thrombosis (DVT). OSPHENA 60 mg had cerebral thromboembolic and hemorrhagic stroke incidence rates of 1.13 and 3.39 per thousand women years, respectively vs....
What it is approved for
From the label in effect Feb 14, 2025.
OSPHENA is indicated for: OSPHENA is an estrogen agonist/antagonist indicated for: The treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. ( 1.1 ) The treatment of moderate to severe vaginal dryness, a symptom of vulvar and vaginal atrophy, due to menopause. ( 1.2 ) 1.1 The Treatment of Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy, due to Menopause. 1.2 The Treatment of Moderate to Severe Vaginal Dryness, a Symptom of Vulvar and Vaginal Atrophy, due to Menopause.
Mechanism: OSPHENA is an estrogen receptor agonist/antagonist with tissue selective effects. Its biological actions are mediated through binding to estrogen receptors. This binding results in activation of estrogenic pathways in some tissues (agonism) and blockade of estrogenic pathways in others (antagonism).
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 25, 2019 Supplement 15 · Efficacy LabelLetter
- Feb 26, 2013 Original approval · Type 1 - New Molecular Entity NovelLabelReviewLetter
1 products under this application
- OSPHENA · OSPEMIFENE 60MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Ospemifene" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual ActivityPivotal-lookingCompleted
ShionogiIndustry
NCT00729469 · 919 participants · Start Jul 2008 · Primary completion Aug 2009
Drug: Ospemifene 60 mg; Placebo · For: Atrophy; Vaginal Diseases
- A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal WomenPivotal-lookingCompleted
ShionogiIndustry
NCT00276094 · 826 participants · Start Jan 2006
Drug: Ospemifene 30 mg; Ospemifene 60 mg and 2 more · For: Atrophy; Vaginal Diseases
- Study to Evaluate Ospemifene in Patients With Moderate to Severe Vaginal Dryness Due to MenopausePivotal-lookingCompleted
ShionogiIndustry
NCT02638337 · 631 participants · Start Jan 26, 2016 · Primary completion Jun 23, 2017
Drug: Ospemifene; Placebo · For: Vaginal Dryness
- A Clinical Study to Evaluate the Safety of OspemifenePivotal-lookingCompleted
ShionogiIndustry
NCT00566982 · 426 participants · Start Oct 2007 · Primary completion Jul 2009
Drug: Ospemifene 60 mg; Placebo · For: Atrophy; Vaginal Diseases
- Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a UterusPivotal-lookingCompleted
ShionogiIndustry
NCT01586364 · 301 participants · Start May 8, 2006 · Primary completion Nov 21, 2008
Drug: Ospemifene 60Mg Oral Tablet · For: Atrophy; Vaginal Diseases
- Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact UterusPivotal-lookingCompleted
ShionogiIndustry
NCT01585558 · 180 participants · Start May 16, 2006 · Primary completion Aug 19, 2008
Drug: Ospemifene (Dose 1); Ospemifene (Dose 2) and 1 more · For: Atrophy; Vaginal Diseases
- A Clinical Study to Evaluate the Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal WomenPivotal-lookingCompleted
ShionogiIndustry
NCT00630539 · 126 participants · Start Aug 2007 · Primary completion Jan 2008
Drug: Placebo; Ospemifene 5 mg and 2 more · For: Atrophy; Vaginal Diseases
- Effects of Ospemifene on Brain Activation Patterns in Women With Sexual Interest-arousal DisordersCompleted
Hospital Clinic of BarcelonaAcademic, hospital or other
NCT04677491 · 25 participants · Start Nov 1, 2021 · Primary completion Nov 1, 2022
Drug: Ospemifene 60 mg · For: Vulvovaginal Signs and Symptoms; Genitourinary Syndrome of Menopause; Sexual; Disorder, Arousal, Female
Sites: Barcelona, Spain
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use452
- hot flush372
- headache209
- muscle spasms194
- no adverse event173
- vaginal haemorrhage150
- vaginal discharge134
- labelled drug-drug interaction medication error111
- nausea108
- hyperhidrosis107
- drug ineffective94
- rash88
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 93 |
| 2014 | 491 |
| 2015 | 446 |
| 2016 | 589 |
| 2017 | 285 |
| 2018 | 419 |
| 2019 | 108 |
| 2020 | 49 |
| 2021 | 37 |
| 2022 | 19 |
| 2023 | 21 |
| 2024 | 17 |
| 2025 | 17 |
| 2026 | 14 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Osphena (Ospemifene)
2024 spending
$7.8M
Beneficiaries
4,417
17,063 claims
Per beneficiary
$1,776
$7.89 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $6,527,448 |
| 2021 | $7,824,454 |
| 2022 | $8,123,385 |
| 2023 | $8,451,359 |
| 2024 | $7,843,923 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Hormonal Treatments and Vaginal Moisturizers for Genitourinary Syndrome of Menopause : A Systematic Review.
Danan ER, Sowerby C, Ullman KE, et al. · Ann Intern Med 2024 · Systematic Review, Research Support, U.S. Gov't, Non-P.H.S.
- Hormone Therapy and Other Treatments for Symptoms of Menopause.
Hill DA, Crider M, Hill SR · Am Fam Physician 2016 · Systematic Review
- Nonestrogen Therapies for Treatment of Genitourinary Syndrome of Menopause: A Systematic Review.
Casiano Evans EA, Hobson DTG, Aschkenazi SO, et al. · Obstet Gynecol 2023 · Systematic Review
- Effects of ospemifene on bone in postmenopausal women.
de Villiers TJ, Altomare C, Particco M, et al. · Climacteric 2019 · Systematic Review
- Safety and Serum Estradiol Levels in Hormonal Treatments for Vulvovaginal Atrophy in Breast Cancer Survivors: A Systematic Review and Meta-Analysis.
Comini ACM, Carvalho BM, Moreira MJB, et al. · Clin Breast Cancer 2023 · Meta-Analysis, Systematic Review
- Vaginal effects of ospemifene in the ovariectomized rat preclinical model of menopause.
Unkila M, Kari S, Yatkin E, et al. · J Steroid Biochem Mol Biol 2013 · Clinical Trial, Phase III
Sponsor: Duchesnay
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.